A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Recruiting Phase 1 Interventional Study
Lung Cancer Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Diagnostic
Participants needed
5 (estimated)
Sponsor
Memorial Sloan Kettering Cancer Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient must be 18 years of age or older at the time of signing the informed consent. * Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer * Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not receive…
Contacts

Adam Schoenfeld, MD

646-608-4042

schoenfa@mskcc.org

CONTACT

Alexander Shoushtari, MD

646-888-4161

shoushta@mskcc.org

CONTACT